LONG-ACTING APRETUDE WAS PROVEN SUPERIOR AT REDUCING THE RISK OF GETTING HIV VS ONCE-DAILY TRUVADA
Randomized, double-blind, controlled clinical trials were used to make the results of the study less likely to be biased.
These clinical trials compared APRETUDE with TRUVADA to see how well APRETUDE worked and how safe it was at preventing HIV-1 in adults at risk of getting HIV-1. Participants were randomly assigned to receive either APRETUDE + TRUVADA placebo or TRUVADA + APRETUDE placebo. Neither participants nor investigators knew which medicine participants were receiving.
The main goal was to measure how many people became infected with HIV-1 during the clinical trials.
More people stayed HIV negative on APRETUDE than on TRUVADA during the studies.
STUDY 1:
4,566 HIV–NEGATIVE CISGENDER MEN, TRANSGENDER WOMEN, AND PEOPLE AT RISK OF GETTING HIV.
Participants were on the product for a median 1.3 years.
HIV transmissions occurred about 3X less often with APRETUDE compared with TRUVADA, which means better HIV protection.
MOST COMMON SIDE EFFECT
The most common side effect reported in participants receiving APRETUDE in Study 1 was injection site reactions (82%). This is not the only side effect of APRETUDE. For more information, see the Risks & Side Effects page. Always tell your doctor if you experience any side effect.
After this portion of the study, participants were surveyed
Of those who responded, 96% of participants chose APRETUDE over daily oral TRUVADA as their PrEP option.
When the trial was complete, participants were offered the choice of continuing the study with APRETUDE or TRUVADA. Of the 1,698 participants originally included from the US, 803 (47%) had choice data available. Individuals preferring an oral PrEP option may have chosen not to enroll in the study.
IN STUDY 1
STUDY 2:
3,224 HIV–NEGATIVE CISGENDER WOMEN AT RISK OF GETTING HIV.
Participants were on the product for a median 1.3 years.
HIV transmissions occurred 12X less often with APRETUDE compared with TRUVADA, which means better HIV protection.
MOST COMMON SIDE EFFECTS
The most common side effects reported in participants receiving APRETUDE in Study 2 were injection site reactions (38%) and headache (12%). These are not the only side effects of APRETUDE. For more information, see the Risks & Side Effects page. Always tell your doctor if you experience any side effect.
After this portion of the study, participants were surveyed
Of those who responded, 78% of participants chose APRETUDE over daily oral TRUVADA as their PrEP option.
When the trial was complete, participants were offered the choice of continuing the study with APRETUDE or TRUVADA. Of the 3,028 patients in the study, 2,472 (81%) had choice data available. Individuals preferring an oral PrEP option may have chosen not to enroll in the study.
IN STUDY 2
APRETUDE is given every other month by a healthcare provider after initiation injections have been given 1 month apart for 2 consecutive months. Stay under a provider’s care while receiving APRETUDE. You must receive it as scheduled. If you will miss a scheduled injection by more than 7 days, call your provider right away.
THROUGH THE ViiVCONNECT COPAY PROGRAM, ELIGIBLE PATIENTS MAY PAY AS LITTLE AS A $0 COPAY PER INJECTION ON PRESCRIBED APRETUDE.*
*The ViiVConnect Copay Program is subject to eligibility and program terms and conditions and is not health insurance.
PMUS-CBTWCNT260024